Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies

Gain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse...

Full description

Bibliographic Details
Main Authors: Oliver Snow, Nada Lallous, Martin Ester, Artem Cherkasov
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/16/5847
id doaj-32b39ff3ccc04873ae5f3c5cad1ac781
record_format Article
spelling doaj-32b39ff3ccc04873ae5f3c5cad1ac7812020-11-25T03:04:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-01215847584710.3390/ijms21165847Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer TherapiesOliver Snow0Nada Lallous1Martin Ester2Artem Cherkasov3School of Computing Science, Simon Fraser University, Burnaby, BC V5A 1S6, CanadaVancouver Prostate Centre, University of British Columbia, 2660 Oak St, Vancouver, BC V6H 3Z6, CanadaSchool of Computing Science, Simon Fraser University, Burnaby, BC V5A 1S6, CanadaVancouver Prostate Centre, University of British Columbia, 2660 Oak St, Vancouver, BC V6H 3Z6, CanadaGain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse responses. However, experimental characterization of these mutations is time consuming and costly; thus, predictive models are needed to anticipate resistant mutations and to guide the drug discovery process. In this work, we leverage experimental data collected on 68 AR mutants, either observed in the clinic or described in the literature, to train a deep neural network (DNN) that predicts the response of these mutants to currently used and experimental anti-androgens and testosterone. We demonstrate that the use of this DNN, with general 2D descriptors, provides a more accurate prediction of the biological outcome (inhibition, activation, no-response, mixed-response) in AR mutant-drug pairs compared to other machine learning approaches. Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments.https://www.mdpi.com/1422-0067/21/16/5847prostate cancerandrogen receptordeep learningproteochemometrics
collection DOAJ
language English
format Article
sources DOAJ
author Oliver Snow
Nada Lallous
Martin Ester
Artem Cherkasov
spellingShingle Oliver Snow
Nada Lallous
Martin Ester
Artem Cherkasov
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
International Journal of Molecular Sciences
prostate cancer
androgen receptor
deep learning
proteochemometrics
author_facet Oliver Snow
Nada Lallous
Martin Ester
Artem Cherkasov
author_sort Oliver Snow
title Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
title_short Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
title_full Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
title_fullStr Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
title_full_unstemmed Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
title_sort deep learning modeling of androgen receptor responses to prostate cancer therapies
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-08-01
description Gain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse responses. However, experimental characterization of these mutations is time consuming and costly; thus, predictive models are needed to anticipate resistant mutations and to guide the drug discovery process. In this work, we leverage experimental data collected on 68 AR mutants, either observed in the clinic or described in the literature, to train a deep neural network (DNN) that predicts the response of these mutants to currently used and experimental anti-androgens and testosterone. We demonstrate that the use of this DNN, with general 2D descriptors, provides a more accurate prediction of the biological outcome (inhibition, activation, no-response, mixed-response) in AR mutant-drug pairs compared to other machine learning approaches. Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments.
topic prostate cancer
androgen receptor
deep learning
proteochemometrics
url https://www.mdpi.com/1422-0067/21/16/5847
work_keys_str_mv AT oliversnow deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies
AT nadalallous deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies
AT martinester deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies
AT artemcherkasov deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies
_version_ 1724680263222427648